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Ascorbic acid (AA) is the active component of vitamin C and antioxidant activity was
long considered to be the primary molecular mechanism underlying the physiological
actions of AA. We recently demonstrated that AA is a competitive inhibitor of adenylate
cyclase, acting as a global regulator of intracellular cyclic adenosine monophosphate
(cAMP) levels. Our study, therefore, aimed to determine new targets of AA that would
account for its potential effect on signal transduction, particularly during cell differentiation.
We demonstrated that AA is an inhibitor of pre-adipocyte cell line differentiation, with
a dose-dependent effect. Additionally, we describe the impact of AA on the expression
of genes involved in adipogenesis and/or the adipocyte phenotype. Moreover, our data
suggest that treatment with AA partially reverses lipid accumulation in mature adipocytes.
These properties likely reflect the function of AA as a global regulator of the cAMP
pool, since an analog of AA without any antioxidant properties elicited the same effect.
Additionally, we demonstrated that AA inhibits adipogenesis in OP9 mesenchymal cell
line and drives the differentiation of this line toward osteogenesis. Finally, our data suggest
that the intracellular transporter SVCT2 is involved in these processes and may act as a
receptor for AA.
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INTRODUCTION
We have previously demonstrated that treatment of a mouse
model of Charcot-Marie-Tooth 1A disease, an inherited periph-
eral neuropathy, with high doses of ascorbic acid (AA) at least
partly reversed the phenotype of transgenic mice (Passage et al.,
2004). In subsequent work, we demonstrated that the intracellu-
lar pool of cyclic adenosine monophosphate (cAMP) decreased
when cells were incubated with increasing concentrations of AA
(Kaya et al., 2007). This inhibition is specific to AA, and is not
elicited by other antioxidants (Kaya et al., 2008b). Using clas-
sic enzyme inhibition experiments, we demonstrated that AA is
a competitive inhibitor of adenylate cyclase (Kaya et al., 2008a).
Through this intracellular effect, AA suppresses the expression of
genes that are under the control of the cAMP signaling pathway.
Additionally, we demonstrated that AA suppresses cell prolif-
eration in vitro, as well as in vivo (Belin et al., 2009). Taken
together, these studies suggest that AA could be an important
factor in the regulation of cell differentiation through its novel
function as a regulator of the intracellular cAMP levels. This novel
perspective led us to investigate the cellular targets of AA that
underlie the observed effects, especially those affected during cell
differentiation.
Adipose tissue is mainly composed of adipocytes that accu-
mulate lipid droplets in the cytoplasm. Moreover, adipocytes
secrete a number of physiologically important molecules, includ-
ing cytokines. Pre-adipocytes, fibroblast-like cells, differentiate
from mesenchymal cells that are in turn derived from the meso-
derm, an embryonic cellular layer that is also a progenitor of
striated muscle and bones. Differentiation of pre-adipocytes into
mature adipocytes has been studied using various mesenchymal
fibroblast-like cell lines, with the majority of studies utilizing the
3T3-L1 cell line.
Increase in body mass index (BMI) is seen as a consequence of
multiple factors, including obesity (genetic and/or nutritional),
age, and environment, among others. Elevated BMI is associated
with an increased risk of a number of disorders, mainly cardio-
vascular, that shorten the life expectancy. In addition to its major
role in lipid storage, adipose tissue functions as an endocrine
organ, influencing metabolism (Spiegelman and Flier, 2001).
Multiple clinical studies report that plasma AA concentration
is inversely related to BMI and fat distribution (Canoy et al.,
2005; Johnston et al., 2007; Aasheim et al., 2008). Additionally,
AA has been reported to interfere with lipid accumulation in
animals fed a high-fat diet (Campión et al., 2006), but no mech-
anism has been proposed to explain these findings. Two broad
molecular mechanisms may account for this effect; one involves
the action of AA on biochemical processes linked to metabolism,
while another putative mechanism involves the effect of AA on
tissue dynamics. Our hypothesis is that AA may be involved
in the second process and affect adipocyte differentiation. The
study described in this manuscript, therefore, has the following
goals:
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1. To evaluate the impact of AA on pre-adipocyte differentiation.
Addition of AA to the cell incubation medium has been long
recognized to impact cell differentiation processes (myelin
formation, osteogenesis, and others), but the mechanism is
largely unknown at this time and active doses are yet to be
determined.
2. To provide information on the signaling pathways involved in
the effect of AA on differentiation.
3. To elucidate how the AA signal is transduced to the cell. No
AA receptor has been identified so far. Could a molecule such
as the transporter SVCT2 play this role?
The gene expression cascade activated during adipocyte differen-
tiation has been largely described. A number of transcriptional
factors were identified as being involved in terminal differenti-
ation of adipocytes, including peroxisome proliferator-activated
receptor γ (PPAR-γ) (Tontonoz et al., 1994; Spiegelman and
Flier, 2001; Puigserver and Spiegelman, 2003), CCAAT-enhancer-
binding proteins (C/EBP) α and β (Umek et al., 1991; Yeh et al.,
1995), and sterol regulatory element-binding protein 1 (SREBP-
1c) (Kim and Spiegelman, 1996; Le Lay et al., 2002). PPARγ and
C/EBP expression are stimulated early in the pre-adipocyte differ-
entiation process. Genes such as adiponectin are expressed later,
as part of the terminal differentiation processes (Musri et al.,
2010). However, the role of non-protein factors that may be
driving cell differentiation is poorly understood.
In this article, we demonstrate that AA inhibits adipocyte dif-
ferentiation in a dose-dependent manner. Moreover, treatment
with AA partially reverses the differentiation of preadipocytes to
mature adipocytes. Additionally, we demonstrate that AA inhibits
adipogenesis in OP9 cell line. Finally, we demonstrate that expres-
sion of sodium-dependent vitamin C transporter 2 (SVCT2),
a transporter protein and a putative AA receptor, is probably
involved in these differentiation processes. Our findings suggest
that these intracellular effects are not linked to the antioxidant
properties of AA, since they also occur following treatment with
an analog without any antioxidant capacity that is capable of
modulating cAMP levels.
MATERIALS AND METHODS
CELLS CULTURE
Mouse 3T3-L1 cells were obtained from ATCC. Pre-adipocytes
cells were cultured in DMEM containing 25mmol/l glucose and
supplemented with glutamax and without pyruvate, 10% (v/v)
FBS, 1% penicillin/streptomycin (100U/ml and 100μg/ml), and
1% biotin/pantothenate. The cells were inoculated into either 6
multidishes at a density of 2 × 104 cells/well for gene expression
assays or 96 wells micro plate at a density of 5 × 103 to evaluate
lipid accumulation. Cells are maintained at 37◦C under a humid-
ified 5% CO2 atmosphere. The numbers of cells were evaluated
with a Neubauer hemocytometer, using 0.05% trypsin-EDTA dis-
sociated cells, and cell viability was monitored by means of the
trypan blue-dye exclusion test.
OP9 cells were cultured in MEM-α containing 20% FBS, 1%
L-glutamine (2mM), 1% penicillin and Streptomycin at 37◦C in
humid field containing 5% of CO2. Cells are let to spontaneously
differentiate during 2 weeks in DMEM + dexamethasone at
10−7 mol/L with or without AA at 100μM.
ADIPOCYTES DIFFERENTIATION
Cells were cultured for 9 days in DMEM containing 25mmol/l
glucose, 10% (v/v) FBS, antibiotics and supplemented with dex-
amethasone (1μmol/L), and insulin (1μg/ml). IBMX was added
or not to the medium. AA was added or not to the medium (dis-
solved in 1× PBS and then filtered). Medium was changed every
2 days.
QUALITATIVE ANALYSIS OF LIPID ACCUMULATION
Cells were rinsed by PBS and fixed with 10% (v/v) buffered for-
malin in Dulbecco’s PBS for 10min. Then formalin discarded and
2ml of fresh formalin was added and incubate for 24 h. Following
fixation, cells were washed by ddH2O twice. The cells were let to
dry at RT. Following drying, Oil Red-O solution (60% in distilled
water) was added and cells incubated for 10min. Cells were rinsed
twice with ddH2O. Pictures were acquired under the microscope.
ADIPORED™ ASSAYS
Cells were seeded at a density of 5 × 103 cells/well (96-wells
plate), and then cultured in DMEM containing 10% FBS and 1%
antibiotics and treated with dexamethasone (1μmol/l), insulin
(1μg/ml), and various concentration of AA for 9 days. Thereafter,
cells were rinsed with PBS. Then AdipoRed™ (LonzaWalkersville,
USA) a dye that binds lipids, and, in different wells, SYBR® Green
I (Life Technology), that binds DNA (as an evaluation of cells
number), were added. Plates were then read on a microplate
reader (VICTOR™X4 from PerkinElmer®) and the fluorescence
of AdipoRed™ and SYBR® Green I were measured with exci-
tation 485 nm/emission 572 nm and excitation 494 nm/emission
521 nm respectively. Adipored fluorescence was normalized to
DNA content.
VON KOSSA STAINING
Cell cultures were fixed in cold methanol for 15–20min. After
rinsing, the fixed cells were incubated with (5%) Silver Nitrate
Solution (abcam product # ab150687) and crosslinked under UV
light for 20–30min, then rinsed twice with distilled water. The
dishes were incubated with (5%) Sodium Thiosulfate Solution for
2–3min, rinsed twice with distilled water; then finally incubated
with Nuclear Fast Red Solution for 5min, and rinsed several times
with distilled water to remove excess stain.
EVALUATION OF cAMP CONCENTRATION
Intracellular cAMP level was measured using cAMP-Glo™ Assay
(Promega Corp.). Briefly, 100μl of 3T3L1 cells solution (5 × 104
cells/ml) was deposited in a sterile 96-wells microplate (cul-
ture treated) and incubated at 37◦C in 5% CO2/95% air. After
cell adhesion (24 h), culture medium was replaced by 20μl of
our compounds solutions, prepared in “induction buffer.” Each
solution dilution was tested in triplicate, and wells contain-
ing 3T3L1 cells in 20μl of induction buffer alone were used
as controls like basal level of intracellular cAMP. Then, assay
was performed according to the manufacturer’s instructions. At
the end, plates were read using a microplate reader (Victor™
X4, PerkinElmer®). According to kit instructions, “Induction
Buffer” was composed with PBS containing 500μM of 3-
isobutyl-1-methylxanthine (IBMX) and 100μM of 4-(3-butoxy-
4-methoxybenzyl)imidazolidin-2-one (Ro20-1724). The IBMX
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and Ro20-1724 are inhibitors of phosphodiesterases and used to
prevent cAMP hydrolysis during the assay. In summary, this assay
evaluates cAMP production, as a consequence of adenylate cyclase
activity.
QUANTITATIVE EVALUATION OF LIPIDS AND MINERALIZATION IN
CELLS CULTURES
Pictures were acquired for stained cells in culture using a Zeiss
microscope. Presence of mineralized nodules and deposited cal-
cium were seen as dark brown to black spots using Von Kossa
staining methods, while lipid accumulation droplets are colored
in red by Oil Red O or appear as white droplet spots. The eval-
uation of lipid droplets and mineralization were quantified by
means of ImageJ software version 1.47. Area presenting brown
coloration, red coloration or white droplets is evaluated in fields
of 7mm2. Ten fields have been evaluated.
GENE EXPRESSION ASSAYS
Total RNA was extracted from cells using TRIZOL reagent
(Invitrogen™) according to the manufacturer’s protocol. Purified
total RNA from adipocytes was reverse transcribed using
Superscript II reverse transcriptase (Invitrogen™) to produce
cDNA. Thereafter, quantitative real time-polymerase chain reac-
tion (PCR) was performed using Light Cycler 480 Real-Time
PCR System (Roche), using UPL probes. Specific primers were
used and described in Table 1. Expression levels of target genes
were normalized using β-actin (ACTB) as internal standard. The
results were treated using the comparative CT method, where the
amount of the target, normalized to the endogenous reference
and relative to a calibrator, is given by 2−CT.
STATISTICAL ANALYSIS
We used Prism v5 software to perform statistical analysis of
data. Data corresponding to an experiment were analyzed using
ranking tests (Wilcoxon and Kruskal–Wallis). Results presenting
a p-value < 0.05 were further analyzed using the Mann–Whitney
two-tailed statistical significance test, with a confidence interval of
95%. We considered a p-value lower than 0.05 as significant. IC50
has been evaluated using the dedicated section of Prism software.
Table 1 | Specific primers used in qPCR experiments.
RNA Primer Sequences (5′ → 3′)
C/EBPα Forward
Reverse
AGCAACGAGTACCGGGTACG
GTTTGGCTTTATCTCGGCTC
C/EBPβ Forward
Reverse
AAGATGCGCAACCTGGAG
CAGGGTGCTGAGCTCTCG
Srebf1 Forward
Reverse
GGTTTTGAACGACATCGAAGA
CGGGAAGTCACTGTCTTGGT
PPARγ Forward
Reverse
GAAAGACAACGGACAAATCACC
GGGGGTGATATGTTTGAACTTG
SVCT2 Forward
Reverse
TGTGCCAGGCTCTCCTGT
GACCCTCCACGAAAATACCC
Adiponectin Forward
Reverse
TCCTGGAGAGAAGGGAGAGAAAG
CAGCTCCTGTCATTCCAACAT
TiMP3 Forward
Reverse
GCCTCAAGCTAGAAGTCAACAAA
TGTACATCTTGCCTTCATACACG
β-actin Forward
Reverse
CTAAGGCCAACCGTGAAAAG
ACCAGAGGCATACAGGGACA
RESULTS
AA INHIBITS DIFFERENTIATION OF MESENCHYMAL 3T3 L1 CELLS INTO
ADIPOCYTES
In a first experiment, we cultured 3T3 L1 cells for 9 days
in a medium that promotes adipocyte differentiation with
IBMX, with and without AA. We observed that cells treated
with 500μmol/L AA present with less fully differentiated
adipocytes, as depicted in Figures 1A,B. The experiment was
repeated using increasing concentrations of AA to establish
the dose-dependence of this effect. At low concentration of
AA (50μmol/L), we observed an increase in lipid accumula-
tion (Figure 1C). However, when concentration of AA increased,
we observed inhibition of lipid accumulation. This result
could be explained by the competition between the effects
of IBMX and AA. Since IBMX increases cAMP levels (by
inhibiting phosphodiesterases), while AA inhibits cAMP pro-
duction (Kaya et al., 2007, 2008a), it becomes obvious that
an increase in AA concentrations counteracts the effect of
IBMX. In order to determine if there is a critical period for
AA action, cells were treated for 3 days with IBMX and AA
at a range of concentrations (Figure 1D) and left to differ-
entiate until day 9. We observed that 3 days of treatment
were sufficient to inhibit lipids accumulation. In a separate
experiment, cells were treated for 3 days with IBMX with-
out any AA, followed by incubation without IBMX, but with
increasing doses of AA. We observed (Figure 1E) that lipid
accumulation in cells that underwent this treatment was not
inhibited by AA, except at a concentration of 500μmol/L.
A schematic representation of these experiments is presented
in Supplementary Figure 1. Our findings suggest the exis-
tence of a critical period for AA action, extending from
day 0–3.
In order to avoid competition between the IBMX-induced
increase in cAMP levels, and AA-mediated decrease, we cul-
tured 3T3 L1 pre-adipocytes in a medium without IBMX for
9 days with or without AA. In these conditions, the per-
centage of cells that differentiated into mature adipocytes was
found to be lower, but we did observe that cells could dif-
ferentiate into adipocytes in cultures without AA (Figure 2A).
The next question was to determine whether inhibition of
lipids accumulation by AA is dose-dependent. As presented in
Figures 2A–F, we observed that lipid accumulation is inhib-
ited in a dose-dependent manner when cells are incubated with
increasing doses of AA. In a further experiment, cells were
cultured in 96-well microplates in a medium without IBMX
and with increasing doses of AA. After 9 days, lipid accumu-
lation was evaluated using an assay developed in our labora-
tory (see Materials and Methods), with the results presented in
Figure 2G. These data demonstrated that inhibition of 3T3 L1
cells differentiation by AA is dose-dependent, with IC50 about
150μmol/L.
EXPRESSION OF SPECIFIC MARKERS OF ADIPOCYTE DIFFERENTIATION
IS INHIBITED BY AA
3T3-L1 cells were cultured for 9 days in a medium without
IBMX with a range of concentrations of AA. RNA was extracted
and expression of specific markers of adipocyte differentiation
evaluated by qPCR. Results are presented in Figure 3. We
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FIGURE 1 | 3T3L1 differentiation. Cells were cultured, with IBMX, during 9
days without AA (A) or with 0.5mM of AA (B). After 9 days cells are stained
with Oil Red O. (C) In an independent experiment 3T3L1 cells were treated
with IBMX during 3 days and cultured without AA and with increasing doses
of AA during a total of 9 days. At the end, AdipoRed is added and
fluorescence recorded (for details see Materials and Methods). Results are
expressed in fluorescence arbitrary units. (D) Cells were treated during 3
days with IBMX and with increasing doses of AA. Cells were then allowed to
differentiate without AA. At the end of the experience (9 days from the
starting point of the experiment) lipids accumulation is recorded using
AdipoRed assay (see Materials and Methods). (E) Cells were incubated with
IBMX during 3 days without AA. Cells were then incubated without IBMX
and with increasing doses of AA. Lipids accumulation was recording, using
AdipoRed assay (see Materials and Methods) after 9 days from the starting
point of the experiment. Schematic representation of our protocol is
presented in Supplementary Figure 1. ∗p < 0.05, ∗∗p < 0.01.
observed that expression of genes associated with adipocyte dif-
ferentiation (CEBP-α and -β, PPAR-γ, and SREB) was lower in
the cells treated with AA compared to that in the cells incu-
bated without AA, and this inhibition was dose-dependent.
Expression of adiponectin, a marker of late stages of differen-
tiation, was also inhibited by AA. Additionally, expression of
TIMP3, which is normally reduced during adipocyte differen-
tiation (Bernot et al., 2010), was elevated in cells treated with
AA (Figure 3F). Expression of these differentiation markers is in
agreement with the proposed inhibitory effect of AA on adipocyte
differentiation.
AA SUPPRESSES THE ACCUMULATION OF LIPIDS IN MATURE
ADIPOCYTES
We demonstrated above that AA inhibits differentiation of mes-
enchymal cells into mature adipocytes. To gain information
regarding the action of AA on mature adipocytes, we cultured
3T3-L1 cells in a medium allowing their differentiation into
mature adipocytes, in the presence of IBMX. When maturation
was observed following 7 days of incubation, the cells were incu-
bated in a medium without IBMX and the culture continued for
7 days with or without AA (0.1 of 0.5mmol/L). At the end of the
final incubation, lipid accumulation was recorded. As presented
Frontiers in Cell and Developmental Biology | Cellular Endocrinology August 2014 | Volume 2 | Article 29 | 4
Rahman et al. Ascorbic acid and adipogenesis
FIGURE 2 | 3T3L1 differentiation. Cells were cultured, without IBMX,
during 9 days without AA (A) or with 50μM (B), 100μM (C), 150μM (D),
250μM (E), and 500μM (F). After 9 days cells were stained with Oil Red O.
(G) In an independent experiment 3T3-L1 cells were cultured with or without
AA. After 9 days, AdipoRed was added and fluorescence recorded (for details
see Materials and Methods). Results are expressed in fluorescence arbitrary
units. ∗p < 0.05, ∗∗p < 0.01.
in Figures 4A–C, we observed that lipid accumulation continued
in the absence of AA, but was decreased when AA is added to the
medium.
These results suggest that AA is able to act on mature
adipocytes, reversing lipid accumulation. However, it will be
interesting to confirm these results using stromal vascular frac-
tion (SVF) of adipose tissue and testing lipid accumulation and
gene expression.
A DERIVATIVE OF AA DEVOID OF ANTIOXIDANT PROPERTIES ALSO
INHIBITS ADIPOGENESIS
AA has been described primarily as an antioxidant, but our recent
work (Kaya et al., 2007, 2008a,b) identified a new function: a
global regulator of cAMP levels through competitive inhibition
of adenylate cyclase. To investigate whether the observed effect
of AA on cell differentiation was due to its direct action on
the cAMP pool or an outcome of its antioxidant properties,
we used K873, an analog of AA recently synthesized in our
laboratory. This molecule did not present any antioxidant prop-
erties but, like AA, it was shown to reduce the cAMP lev-
els, although at lower concentrations (Bordignon et al., 2013).
Treatment of 3T3-L1 with K873 during adipocyte differentiation
inhibited the expression of adipocyte markers (C/EBPβ, PPAR-γ,
and adiponectin), as observed in Figure 5. This result indicates
that inhibition of adipocyte differentiation by treatment of pre-
adipocytes with K873 is likely to result from its effect on cAMP
levels.
CYCLIC AMP IS INVOLVED IN THE EFFECTS OF AA AND K873
While we have previously described a reduction of cAMP levels
following treatment with AA in different cell types, this effect
has never been evaluated in mesenchymal pre-adipocytes. We
tested 3T3L1 incubated without AA or with increasing concen-
trations of AA, and evaluated the intracellular cAMP concentra-
tion. Results are presented in Figure 6A. We observed that AA
decreased intracellular cAMP concentration in a dose-dependent
manner. Moreover, we incubated 3T3L1 with dibutyril-cAMP
(db-cAMP) alone or in the presence of IBMX without adding
AA. We observed that addition of these compounds increased
lipid accumulation, as was previously shown. Additionally, we
treated 3T3L1 cells with db-cAMP and added AA to the
medium. Adding AA inhibited lipid accumulation stimulated by
db-cAMP (Figure 6B).
Taken together, our data confirm that increasing intracellu-
lar cAMP concentration promotes adipogenesis, while lowering
intracellular cAMP levels through treatment with AA inhibits
adipogenesis.
TREATMENT WITH AA INHIBITS DIFFERENTIATION OF OP9 CELLS INTO
ADIPOCYTES, BUT DRIVES IT TOWARD OSTEOGENESIS
In order to rule out the possibility that the observed prop-
erties of AA are specifically linked to the 3T3 L1 cell line,
we analyzed the effect of AA on differentiation of OP9 cells.
This cell line has adipogenic capacity, but could also differ-
entiate into osteogenic cells, depending on the culture condi-
tions (Gao et al., 2010). In addition to evaluating the impact
of AA on adipogenic differentiation, this analysis provided us
with data regarding the impact of AA on osteogenic differ-
entiation, another mesodermic lineage. We treated OP9 cells
with a medium promoting adipocyte differentiation, with or
without AA. After 21 days of culture, cells were stained
either with Oil Red O to label lipids or with Von Kossa
staining to highlight osteogenic differentiation. As shown in
Figure 7, we observed that OP9 cells without AA treatment
differentiate into adipocytes. Conversely, cells treated with AA
poorly differentiated into adipocytes but exhibited clear signs
of osteogenic differentiation. These data suggests that AA
drives adult mesodermic mesenchymal cells to differentiate
following the osteogenic pathway and inhibits adipogenic
differentiation.
SVCT2, THE INTRACELLULAR TRANSPORTER OF AA, IS INVOLVED IN
ITS EFFECTS
Little is known about a putative receptor of AA. However, the
presence of the transport/receptor of AA, SVCT2, was shown to
be required for AA signaling in various conditions (Sotiriou et al.,
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FIGURE 3 | Markers expression. 3T3 L1 were cultured without IBMX and
without or with different concentrations of AA. RNAs were extracted after 9
days and expression of different genes, CEBPα (A), CEBPβ (B), PPARγ (C),
SREBf1 (D), Adiponectin (E), and TIMP3 (F) have been evaluated using qPCR
(see Materials and Methods). Basic levels, expression without incubation
with AA is set to 1 and relative levels evaluated. ∗p < 0.05, ∗∗p < 0.01.
2002). SVCT2 is a transmembrane protein present in a number of
cell types that exhibits high specificity for AA and could act as its
receptor. Therefore, we evaluated the expression of the gene cod-
ing for this protein during adipocyte differentiation. We observed
that the expression of this gene decreased during differentiation
(Figure 8A), with almost no expression of this gene detected in
mature adipocytes. Additionally, we observed that treatment with
AA increased SVCT2 expression in a dose-dependent manner
(Figure 8B). Several articles (Reidling et al., 2008; Wu et al., 2008;
Bordignon et al., 2013; Hong et al., 2013) report that a decrease
in gene expression is correlated with a decrease in concentration
of the corresponding protein SVCT2. In addition, these articles
report that variations in expression of the gene coding for SVCT2
have an impact on various biological processes.
In conclusion, mature adipocytes, under normal conditions,
could probably not receive signals from AA present outside cells.
Pre-adipocytes treated with AA, however, continue to receive the
AA signal, as evidenced by the removal of repression of SVCT2
expression.
DISCUSSION
Several publications suggest that AA may be involved in cell
differentiation, including a study that investigated Schwann
cell differentiation and myelination. This work demonstrated
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FIGURE 4 | 3T3L1 and dedifferentiation. Cells were cultured during 7
days with IBMX, allowing full differentiation. Medium is discarded and
replaced with a medium without IBMX either not supplemented (A) or
supplemented with 0.1mM AA or 0.5mM (B). After 9 days, AdipoRed was
added and fluorescence recorded (for details see Materials and Methods),
(C). Results are expressed in fluorescence arbitrary units. ∗p < 0.05,
∗∗p < 0.01.
FIGURE 5 | Treatment of preadipocytes with K873, an analog of AA.
3T3 L1 were incubated without or with AA during 9 days in an adipogenic
medium. RNAs have been extracted and expression of CEBPβ (A), PPARγ
(B), and adiponectin (C) was evaluated. ∗∗p < 0.01.
that AA should be added to Schwann cells/axons co-culture to
induce myelin formation. Moreover, we demonstrated that high
concentrations of AA promote remyelination in a mouse model
of CMT type 1A disease (Passage et al., 2004). A second line of
research has been recently initiated and investigates the differ-
entiation of embryonic stem cells (ES). Using high-throughput
screening, Takahashi et al. identified AA as the only molecule
present in the searched chemical library that was able to promote
differentiation of murine ES into cardiomyocytes (Takahashi
et al., 2003).
Finally, Sotiriou et al. described a phenotype of a genetic
mouse model in which the SVCT2 gene has been invalidated.
When homozygotic cells are placed in an environment with
normal outside AA concentration, the molecule is unable to
enter the cells. Embryos died in a perinatal period, with lung
and blood vessel anomalies noted (Sotiriou et al., 2002). In
addition, Gess et al. demonstrated that heterozygotes in this
model exhibit a defect in myelination and present a CMT-
like phenotype (Gess et al., 2011). These observations pro-
vide the rationale for investigating the role of AA as a sig-
naling molecule modulating development and differentiation of
mammals.
AA was demonstrated to be essential for the stimulation
of myelin formation in osteogenesis. In our current study, we
demonstrate that AA inhibits the differentiation of mesenchy-
mal cells into mature adipocytes. Two independent cell lines
have been used in this investigation (3T3 L1 and OP9), with
the same results. Our observations appear to contradict previ-
ously published reports, but the differences in outcomes could
be explained by the approaches used. Firstly, several papers
did not use AA itself, but rather its phosphate salts (Ono
et al., 1990; Choi et al., 2008). In one publication that did
use AA (Weiser et al., 2009), the experiments described were
performed at a low concentration (50μmol/L) in bone marrow-
derived cells. In our current manuscript, we show slight stimu-
lation of differentiation to adipocytes of pre-adipocytes treated
with IBMX (a molecule that increases intracellular cAMP con-
centration) and a low concentration of AA (an inhibitor of
adenylate cyclase). However, increasing concentrations of AA
led to an inhibition of differentiation to adipocytes, likely as a
result of a competition between IBMX and AA, with increas-
ing concentrations of AA suppressing the effect of IBMX. In
order to avoid the competition between IBMX and AA, the
effect of AA was also assessed on the “spontaneous” differen-
tiation to adipocytes, without IBMX stimulation. In these con-
ditions, although differentiation is less efficient, we show that
AA inhibits the differentiation to adipocytes with IC50 about
150μmol/L.
In a further step, we evaluated the expression of specific
markers of differentiation. We observed that AA inhibits the
expression of genes (C/EBP, SREB, PPAR-γ, and adiponectin)
involved in different stages of adipocyte differentiation (Kim
et al., 2010). Regulation of these genes shares a common fea-
ture, with their expression being under direct or indirect control
by cAMP and cAMP-dependent pathways (Kim et al., 2010).
This finding confirms previously published data demonstrat-
ing that adipocyte differentiation is driven by cAMP-dependent
pathways (Jia et al., 2012; Kadota et al., 2012). Additionally,
a recent publication (Zhang et al., 2012) demonstrated that
high intracellular cAMP concentration drives ES cell differenti-
ation toward adipocytes. Conversely, low cAMP concentration
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FIGURE 6 | cAMP, AA, and adipocyte differentiation. (A) 3T3L1 have
been incubated without and with AA at increasing concentration. At
the end cAMP concentration was evaluated as described (see
Materials and Methods). (B) 3T3L1 cells were treated either with
dibutyrylcAMP (dBcAMP), dBcAMP+IBMX, or dBcAMP plus AA at
two doses. Lipids accumulation has been evaluated using adipored
technique (see Materials and Methods). Fluorescence has been
recorded. ∗∗p < 0.01.
FIGURE 7 | OP9 cell differentiation. OP9 cells were cultured in a medium
(see Materials and Methods) without AA (A,C) or with AA (B,D). After 21
days, cells have been stained either with Oil Red O (A,B) or with Von Kossa
Staining (C,D). Pictures have been captured using a Zeiss light microscope.
Surface of fields presenting Von Kossa staining (E) or Oil Red O staining
(F), was evaluated using ImageJ software package. ∗∗∗p < 0.001.
FIGURE 8 | Expression of SVCT2 during 3T3L1 differentiation. (A) Cells
were cultured in a medium with IBMX, allowing full differentiation, without
AA. RNAs are extracted after 3, 6, and 9 days of culture. Expression of
SVCT2 is evaluated using qPCR and specific primers (see Table 1) (B).
Adipocytes have been cultured in a medium without IBMX, as described in
Figure 3, and with increasing concentrations of AA. Expression of SVCT2
was evaluated using qPCR. ∗∗p < 0.01.
inhibits adipocyte differentiation and promotes differentiation
of ES cells to osteoblasts (Kao et al., 2012). This modulation is
of particular interest, considering our demonstration that AA,
as a competitive inhibitor of adenylate cyclase, is a regulator
of cAMP levels (Kaya et al., 2008a) and lowers intracellular
concentration of cAMP at increasing concentrations. Our find-
ings are further validated by the inhibition of adipogenesis by
K873, an analog of AA without any antioxidant properties that
modulates intracellular cAMP levels (Bordignon et al., 2013).
Additionally, we demonstrated in current study that stimula-
tion of adipogenesis by db-cAMP and IBMX is inhibited by
treatment with AA at concentrations we have shown to be
effective in reducing cAMP levels. It is thus likely that AA
directly affects adipogenesis by modulating intracellular cAMP
levels.
An interesting further question is what is the effect of AA
on other lineages? We provide data showing that in addi-
tion to inhibiting adipogenic differentiation, AA promotes
osteogenic differentiation. Kao et al. (2012) have demon-
strated that cAMP signaling directs the differentiation of
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mesenchymal cells into osteoblasts, rather than adipocytes. We
observe the same phenomenon with AA, a modulator of cAMP
levels.
Finally, we observed that AA counteracts the repression
of expression of SVCT2 (the transmembrane transporter of
AA) that is known to take place during adipocyte differ-
entiation. This phenomenon could allow cells to receive the
AA signal leading to the repression of adipocytes differen-
tiation. SVCT2 may therefore function as an AA receptor,
with AA treatment increasing the expression of the SVCT2
gene. This suggests that repression of SVCT2 expression dur-
ing the differentiation of pre-adipocytes into mature adipocytes
is partially reversed by AA treatment, allowing cells to receive
the AA signal and leading to a repression of adipocyte
differentiation.
In addition, we have shown that treatment of mature
adipocytes with AA prevents lipid accumulation. At this point, it
is not possible to determine whether this observation reveals ded-
ifferentiation of mature adipocytes, lipolysis, or a novel unknown
mechanism. However, the observation is interesting, as it suggests
that lipid accumulation in mature adipocytes could be modulated
by AA treatment.
Finally, present data could explain why animals fed a high-
fat diet accumulate fewer lipids when treated with AA (Campión
et al., 2006). In addition, these observations could help us
understand why low AA plasma level, in humans, are corre-
lated with obesity and fat distribution (Canoy et al., 2005;
Johnston et al., 2007; Aasheim et al., 2008). The last ques-
tion to be addressed in the evaluation of AA effect would be
whether the concentrations of AA necessary for the inhibi-
tion of adipocyte differentiation (IC50 100μmol/L) could be
achieved by oral administration. During a clinical trial evaluat-
ing the effects of treatments with CMT1A and AA, we measured
blood AA concentrations in participants divided into 3 treat-
ment arms (60 in each arm) and treated during one year. Patients
treated with placebo had an average concentration of 50μmol/L,
patients treated with 1 g/day had an average concentration of
80μmol/L, while patients treated with 3 g/day had an aver-
age concentration of 106μmol/L, reaching up to 160μmol/L
in some subjects (Micallef et al., 2009). A consensus of other
studies is that oral supplementation with increasing doses of
AA does not result in a corresponding increase in blood lev-
els, since the excess of AA is excreted. This conclusion is based
on numerous results of short-term postprandial experiments.
However, our clinical data suggest that long-term supplementa-
tion with increasing doses increases blood levels of AA. While
it is not clear why the findings with long-term treatment con-
tradict the results of short-term experiments, our data suggest
that AA concentrations in blood could be increased through oral
supplementation. In addition, our clinical study has also shown
that there are no adverse effects associated with treatment of
patients with 3 g/day dose of AA, as compared to the placebo
treatment, demonstrating that administration of this dose is safe
for human use.
AA, as well as its derivatives, could therefore modulate cell sig-
naling, with properties that could be of interest for applications
in human health.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at: http://www.frontiersin.org/journal/10.3389/fcell.2014.00029/
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